← Human Trials & Peer-Reviewed Studies
Quality of Life in Adolescent Boys with Idiopathic Short Stature: Positive Impact of Growth Hormone and Aromatase Inhibitors.
Plain-language guide to PMID 30820008 (2018): randomized and open-label clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 30820008
- Journal
- Hormone research in paediatrics
- Year
- 2018
- Study type
- Clinical Trial
- Authors
- Bullinger M et al. (11 authors)
- DOI
- 10.1159/000496353
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.
The condition-specific Quality of Life in Short Stature Youth questionnaire was used to assess QoL.
Why It Was Studied
This study assesses whether GH, AI, or their combination impacts the QoL of adolescent males with idiopathic short stature (ISS) from both the adolescent and the parent perspective.
Who Took Part
The age groups tagged for this paper are teenagers, men only.
How the Study Was Run
In design terms this was a randomized and open-label study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
What Was Measured
This study assesses whether GH, AI, or their combination impacts the QoL of adolescent males with idiopathic short stature (ISS) from both the adolescent and the parent perspective.
Topics PubMed links to this paper include Aromatase Inhibitors, Growth Disorders, Human Growth Hormone, Quality of Life and Surveys and Questionnaires.
Author keywords: Adolescent, Body height, Growth hormone therapy, Idiopathic short stature and Quality of Life in Short Stature Youth questionnaire.
What This Means in Plain Language
The paper is a randomized and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Hormone research in paediatrics), a journal based in Switzerland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.